|
|
|
Subscribe
|
|
|
Contact
|
|
|
Spring ahead with fresh ideas and insights
Welcome to the Spring edition of Access Point. In keeping with this season’s sense of renewal, we’re hoping to refresh your ideas for making the most of your Spectra Optia™ Apheresis System. That’s because we’re highlighting four protocols you may not have realized you can perform on the device. In this issue, you’ll also discover an interesting bit of cell therapy trivia and find the answer to an important question about using an alternative anticoagulant for one particular protocol.
We hope this issue brings you renewed enthusiasm for the versatile functionality of Spectra Optia in helping you deliver the best care possible. As always, if you have ideas on topics you’d like to see covered in future issues, please let us know.
|
|
|
|
Therapeutics and Collections
|
|
Four protocols you may not know you can perform on Spectra Optia
|
|
|
|
You’re probably familiar with using the Spectra Optia device for red blood cell exchange and therapeutic plasma exchange. You may also have learned about using the device for continuous mononuclear cell collection in our December 2024 issue. But you may not know about four additional protocols you can perform with Spectra Optia that can help you give optimal care to even more patients.
In this article, we share insights on those protocols: mononuclear cell collection, granulocyte collection (also known as polymorphonuclear cell collection), bone marrow processing, and white blood cell depletion.
|
|
|
|
Dear Access Point,
We currently do not have hydroxyethyl starch (HES) and trisodium citrate to use as anticoagulant for our granulocyte collection (PMN) procedures and will need to use ACD-A instead. Can you explain how this may impact our PMN procedures on Spectra Optia and what we can do to optimize our runs? — Tracy, Columbus, OH
Dear Tracy,
As you may know, HES is a sedimenting agent that causes granulocytes to separate more efficiently from the red blood cell (RBC) layer in the connector during a PMN procedure. Without it, you may experience lower collection efficiency. However, you can use ACD-A. To do so, first confirm that No for HES is selected on your configuration or option screen. Then consider making the additional adjustments below to optimize the procedure.
- Process more whole blood than the default of 6,000 mL. This will increase the run time and the volume that is collected.
- Decrease the collection preference to collect more cells closer to the RBC interface. The color of the contents in the collect line should appear slightly darker than the darkest color on the Collection Preference tool.
- Increase the packing factor above the default of 4.5 automatically assigned when using ACD-A. Be aware that this could result in an excess number of platelets collected. The procedure will continue in a Caution status, and the system will display a warning screen with instructions for monitoring the patient for platelet depletion.
- Increase the collect pump flow rate above the default flow rate. This results in more cells being collected and a larger collected volume.
|
|
|
|
If you have a specific question about the Spectra Optia system, let us know. We will feature a reader question in each Access Point edition. Be sure to tell us your first name, hometown, and state or province. Questions not featured will be answered directly via email.
|
|
|
|
|
|
|
|
|
|
|
|
Discover the many protocols available on Spectra Optia, along with details such as compatible software and sets, all presented in an
easy-to-read, at-a-glance format.
|
|
|
|
|
|
Did You Know?
Granulocyte transfusions may be the oldest form of cell therapy
Granulocyte transfusions were first used in the early 1970s.1 They are occasionally given as a treatment to patients suffering from severe neutropenia caused by potentially life-threatening bacterial and fungal infections.
Once collected, granulocyte products have a short shelf life, because viability reduces with every hour following donation.2 For example, in England, granulocytes are provided as a pooled component from the National Health Service Blood and Transplant.2 This pooled component is considered to have a one-day shelf life based on a 5% reduction in cell viability and 50% reduction in migration assays at 48 hours.2
|
|
|
|
Succession Workshops: Red Blood Cell Exchange and Cell Collections
May 14 (RBCX) and 15 (CMNC), 2025 | Medstar Georgetown University Hospital, Washington, D.C. For details, see the event invitation sent to local sites or email Sucessions@TerumoBCT.com.
Live From Lakewood
- Veda™ Solutions Overview | May 15, 2025
- AC Management on the Trima Accel™ Automated Blood Collection System | July 17, 2025
- Imugard™ WB PLT Platelet Pooling Set Overview | September 18, 2025
- AC Management on the Spectra Optia Apheresis System | November 13, 2025
All sessions are scheduled for 12 p.m. Mountain Time. Learn more and register to attend any of these live and interactive webinar sessions from our headquarters in Lakewood, Colorado. If you would like to have a specific topic covered in one of these webinars, please send us an email.
|
|
|
|
|
|
You're on the front lines of care, and we're here to assist.
|
|
|
|
|
|
|
|
could help you make the most of your Spectra Optia system and your relationship with
Terumo Blood and Cell Technologies to do even more for your patients.
|
|
|
|
|
|
1Sahlin A, Blomgran R, Berlina g. Granulocyte concentrates prepared from residual leukocyte units produced by the Reveos automated blood processing system. Transfus Apher Sci. 2020 Apr;59(2):102682. doi: 10.1016/j.transci.2019.102682
2Morton S, Fleming K, Stanworth SJ. How are granulocytes for transfusion best used? The past, the present and the future. Br J Haematol.
2023 Feb;200(4):420-428. doi: 10.1111/bjh.18445
IMUGARD™ is either a registered trademark or trademark owned by Terumo Corporation or its affiliates. Spectra Optia™, Trima Accel™, and Veda™ are either registered trademarks or trademarks of Terumo BCT, Inc. in the United States and/or other countries. See TerumoBCT.com/Trademarks for details.
|
|
|
|
©2025 Terumo BCT, Inc. | All Rights Reserved | TS-OPTI-02561 | TerumoBCT.com
|
|
|
|
|
